Nutra Pharma Corp, a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its medical devices division, Designer Diagnostics, has developed a rapid diagnostic test kit for Tuberculoses and will be conducting clinical trials at National Jewish Hospital in Denver, Colorado.
“With the recent scare out there of XDR-TB and MDR-TB, we believe that our test kit technology will help contribute to limiting the spread of the Tuberculosis around the world” explained Rik J Deitsch, Chairman of Nutra Pharma Corp. “We are working closely with world renowned researchers, Dr. Charles Daley and Dr. Leonid Heifets, at National Jewish Hospital to complete our clinical trials and our third-party validation,” he added.
Recently, a US passenger flying on transatlantic flights to and from Europe was diagnosed with a contagious form of XDR-Tuberculosis. This has caused a need for a rapid diagnostic testing of all the passengers and crew onboard those flights. Today, the infected passenger was transferred to National Jewish Hospital, as it is the leading research and treatment hospital for Tuberculosis.
“Over 14 million people are diagnosed with Tuberculosis around the world and 2 million patients die each year from the infectious disease,” commented Neil Roth, President of Designer Diagnostics, Inc. “Current testing can take up to 8-10 weeks for results, where as the Designer Diagnostic test kits have shown results in as little as 8-10 days. Once our test kits complete third party validation at National Jewish Hospital, we believe that our test kits will help save patient lives,” he concluded.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The development of the tuberculosis test kit technology should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.